Nenoxin (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. The drug‑receptor complex then moves into the cell nucleus and alters gene expression, increasing anti‑inflammatory proteins and decreasing pro‑inflammatory cytokines, which reduces swelling and mucus production in the nasal mucosa.

The exact dosing regimen for Nenoxin is determined by the prescribing healthcare professional. In clinical practice, the typical approach is one or two sprays per nostril once daily, but the prescriber may adjust frequency, number of sprays, or treatment duration based on the individual’s age, severity of symptoms and response to therapy.

Safety data for mometasone furoate monohydrate in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant. Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Nenoxin with their healthcare provider.

To request Nenoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Nenoxin (mometasone furoate) is a high‑potency intranasal glucocorticoid with a low systemic bioavailability, similar to other agents such as fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in controlling allergic rhinitis symptoms, while the once‑daily dosing schedule of mometasone may offer convenience for some patients.

Nenoxin should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed when not in use, protect it from moisture and direct sunlight, and keep it out of reach of children. Do not freeze the product.

Nenoxin is delivered as a metered‑dose nasal spray. Before first use, prime the pump by spraying a few times into the air. Tilt the head slightly forward, insert the nozzle into one nostril, close the opposite nostril with a finger, and gently press the actuator while breathing in through the nose. Repeat in the other nostril if prescribed.

Serious adverse events associated with nasal mometasone include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and increased intra‑ocular pressure that may precipitate glaucoma. Patients should seek immediate medical attention if they notice persistent nosebleeds, visual changes, or signs of systemic corticosteroid effects.

Nenoxin should be avoided in individuals with a known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with untreated fungal, bacterial or viral infections of the nasal passages, and in children younger than two years unless specifically directed by a physician.